Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02633033 · ClinicalTrials.gov registry record
Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse
A clinical trial of Multiple Sclerosis (Relapsing Remitting), sponsored by Mallinckrodt.
- Completed
- Registry status
- 160
- Enrollment target
- 20
- Study locations
NCT02633033 is a study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Mallinckrodt. The registered enrollment target is 160 participants, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02633033, a study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
Acthar Gel was first approved by the Food and Drug Administration in 1952. It has been used to treat many different illnesses, including multiple sclerosis. This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS. It will collect information on symptoms, recovery, treatment patterns and safety outcomes.
Conditions Studied
Study Locations (20)
Florida
- Emery Neuroscience Center - Lighthouse PT
- Neurology Associates - Maitland
- Cordova Research Institute - Miami
- Collier Neurologic Specialists - Naples
- Florida Neurological Center - Ocala
- Neurological Services of Orlando - Orlando
- Neurology Associates of Ormond Beach - Ormond Beach
- Negroski, Sutherland and Hanes Neurology - Sarasota
- Infinity Clinical Research - Sunrise
Georgia
- Columbus Research & Wellness Institute - Columbus
- Neurology of Central Georgia - Macon
- Meridian Clinical Research - Savannah
Colorado
- Colorado Springs Neurological Associates - Colorado Springs
- Advanced Neurosciences Research - Fort Collins
Alabama
- Alabama Neurology Associates - Homewood
Arizona
- Territory Neurology & Research Institute - Tucson
Connecticut
- Associated Neurologists of Southern Connecticut - Fairfield
District of Columbia
- MedStar Health - Washington D.C.
Kansas
- College Park Family Care Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2015-11-24 |
| Est. Completion | 2019-05-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02633033
The ClinicalTrials.gov registry entry for NCT02633033 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (71% lower). The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 0 interventions.
NCT02633033 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Georgia, Colorado.
Frequently Asked Questions
What is clinical trial NCT02633033 about?
NCT02633033 is a clinical study titled "Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse". Acthar Gel was first approved by the Food and Drug Administration in 1952. It has been used to treat many different illnesses, including multiple sclerosis. This study will observe how treatment with Acthar affected the daily lives of patients who suffer with relapsing/remitting MS. It will colle...
What is the current status of trial NCT02633033?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2015-11-24. Estimated completion is 2019-05-09.
What conditions does trial NCT02633033 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
Who is sponsoring clinical trial NCT02633033?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02633033 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
MS-ResearchBiomarkerS
RECRUITING
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.